Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07868016
ABSTRACT:
A pharmaceutical formulation suitable for multi-dose administration comprising endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxanide hydrochloride, a preservative selected from the group consisting of alkyl paraben and phenol, and a buffer selected from the group consisting of acetate and phosphate buffers is disclosed.
REFERENCES:
patent: 4886808 (1989-12-01), King
patent: 5935972 (1999-08-01), Naylor et al.
patent: 6239147 (2001-05-01), Obach et al.
patent: 6294548 (2001-09-01), James
patent: 2004/0022755 (2004-02-01), Kamath
patent: 2005/0142073 (2005-06-01), Watts et al.
patent: 2005/0186637 (2005-08-01), Yu et al.
patent: WO 03/003957 (2003-01-01), None
patent: WO 2005/056008 (2005-06-01), None
Physicians' Desk Reference, 56thedition (2002), p. 2986.
Rowe, R.C. et al., “Handbook of pharmaceutical excipients,” 4th edition 2003, Pharmaceutical Press, XP002403743; pp. 390-394; p. 391, paragraph Stability and Storage Conditions pp. 526-528.
Singh Kiran Pal
Yuen Pui-Ho
Baxter Healthcare S.A.
Baxter International Inc.
K&L Gates LLP
Spivack Phyllis G.
LandOfFree
Pharmaceutical formulations of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707094